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Introduction

Tolterodine, (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine,
is an antimuscarinic drug for the treatment of overactive bladder. In humans, tolterodine is mainly eliminated by metabolism, with slight excretion into urine (Postlind et al., 1998) . There are two different oxidative metabolic pathways, hydroxylation and N-dealkylation, that have been identified in humans (Postlind et al., 1998) .
Hydroxylation to the pharmacologically active 5-hydroxymethyl metabolite (5-HM) is the predominant metabolic pathway which is catalysed by cytochrome P450 (CYP) 2D6, while the minor N-dealkylation pathway is mediated by CYP3A (Postlind et al., 1998) .
5-HM itself is metabolized by two major pathways of CYP2D6 and CYP3A4 and it is also renally excreted (Malhotra et al., 2008) . Preclinical studies have demonstrated that 5-HM is pharmacologically equipotent compared with tolterodine in vitro, and has similar functional bladder selectivity in vivo (Nilvebrant, 2000) .
It is well established that CYP2D6 is subject to genetic polymorphism (http://www.cypalleles.ki.se/cyp2d6.htm). Over 70 CYP2D6 allelic variants have been discovered thus far (Zhou, 2009) . They are classified as functional, non-functional and reduced functional groups (Bradford, 2002) . CYP2D6 allele frequency is known to vary among ethnic groups. Generally, for Europeans, the functional group of alleles are predominant with the presence of non-functional alleles mainly as CYP2D6*4. On the other hand, Asians and their close descendants have a low frequency of homozygous of non-functional alleles whereas they have a high frequency of the reduced function allele, CYP2D6*10 (Bradford, 2002; Ozawa et al., 2004; Ingelman-Sundberg, 2005; Bernard et al., 2006) .
In extensive metabolizers (EM) of CYP2D6, the mean systemic clearance of tolterodine was found to be 44 L/h with a half-life of 2-3 h (Brynne et al., 1998) . In contrast, poor metabolizers (PM) have 5-times lower clearance (9 L/h) with a mean half-life of 9 h.
The levels of 5-HM are similar to those of tolterodine in EM and not quantifiable in PM 
Materials and Methods
Subjects
A total of 72 Asian (Japanese and Koreans, 24 male and 48 female) and 36 Caucasian (12 male and 24 female) subjects received tolterodine administration in this study.
Concomitant use of any other medication was not permitted. The study was performed in accordance with the latest revisions to the Declaration of Helsinki, ethical approval having been obtained from the local Institutional Review Board of Health and Regulatory Affairs Authority. All volunteers gave their written informed consent prior to commencement of the study.
Study design
This was a randomized, multiple-dose study in healthy Asian and Caucasian subjects.
The doses were administered as prolonged release capsules (PR). There were three dose groups of 2-, 4-, and 6-mg tolterodine L-tartrate, each group including 36 subjects. Each subject received daily single doses of tolterodine PR for 5 consecutive days.
CYP2D6 genotyping
Genotyping was conducted via DNA purification from whole blood prior to the first dosing and DNA was extracted using Gentra 'PureGene' kit method. The presence of CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*10 was tested for each subject. They were determined using multiplex polymerase chain reaction (CYP2D6*3 and *4), long-range polymerase chain reaction (CYP2D6*5) and allele specific amplification (CYP2D6*10), respectively (PPGx, Cambridge, UK and CYP2D6*5/*10) and PM (CYP2D6*4/*4).
Pharmacokinetic sampling
Venous blood samples for determination of tolterodine and 5-HM were drawn. Steady state sampling was carried out at 0, 0.5, 1, 2, 3, 4, 6, 9, 12, 18 and 24 hours after the last administration. The blood samples (7 mL) were collected at each point in evacuated collection tubes without additives. The blood samples were allowed to coagulate for 45 minutes to 1 hour, after which serum was separated by centrifugation (1,000 x g for 10 minutes) at room temperature. The serum samples were stored frozen at -20°C until analyzed.
A blood sample in connection with the pre-dose sample on the last dosing day was taken for determination of α 1 -acid glycoprotein (AGP).
Analytical methods
Serum samples were assayed for tolterodine and 5-HM using a validated high-performance liquid chromatography with tandem mass spectrometry (LC/MS/MS) method (AAI Deutschland GmbH & Co. KG, Germany). Stable isotope analogues of
mandelate) were used as the internal standards, respectively. The compounds were separated from the serum by solid phase extraction using octadecyl (C18) columns. The resulting extracts were analyzed by LC/MS/MS using Zorbax SB-CN column, mobile phase composed of 60% ammonium acetate (10 mM), 30% methanol, 10% acetonitrile and 0.1% formic acid. The calibration standards for serum concentration assay were linear over the range of 0.1-100 ng/mL. The lower limit of quantitation for both
tolterodine and 5-HM was 0.1 ng/mL. Assay accuracy for tolterodine and 5-HM was 0.2%-3.3% and -3.5%-0.9%. Assay precision for tolterodine and 5-HM was 4.5%-7.4%
and 4.6%-6.9%, respectively.
Pharmacokinetic analysis
Pharmacokinetic parameters after multiple dosing were calculated based on serum concentrations of tolterodine and 5-HM. The calculations were performed by non-compartmental analysis using the Kinetica software (version 3.1; InnaPhase, PA, USA). The maximum serum concentration (Cmax) and area under the concentrationtime curve from 0 to 24 h after the dose (AUC 0-24 ) after multiple dosing were dose normalized to 4 mg for the comparison among genotypes because linear pharmacokinetics of tolterodine was confirmed up to 8 mg (Clemett and Jarvis, 2001).
Serum concentrations for the active moiety were calculated using serum concentration data for tolterodine and 5-HM, and individual AGP concentrations. The fraction unbound (fu) was calculated as follows (Pahlman and Gozzi, 1999) :
where fu tolterodine and fu 5-HM are unbound fraction of tolterodine and 5-HM, respectively.
The concentration of the active moiety = (fu tolterodine x serum concentration of tolterodine) + (fu 5-HM x serum concentration of 5-HM).
For the calculation of active moiety concentration, serum concentrations of tolterodine and 5-HM were converted to molar concentrations (nM) using the molecular weights of tolterodine (325.5) and 5-HM (341.5). to be statistically significant when P values were less than 0.05. Additionally, simulation of the change of exposures was conducted using SAS.
Results
Genotyping
The allele frequencies of CYP2D6*10 in Asian and Caucasian subjects were 40% and 1.4%, respectively. The allele frequency of CYP2D6*5 was 5.6% in Asians and 1.4% in
Caucasians. There were no Asian subjects who had CYP2D6*4 allele but the allele frequency of CYP2D6*4 in Caucasians was 16.7%. Demographics of subjects in each genotype are provided in Table 1 .
Pharmacokinetics
The dose-normalized Cmax and AUC 0-24 of tolterodine, 5-HM and active moiety after multiple dosing are summarized in Table 2 , and are plotted in Figure 1 , Figure 2 and (Table 3) . Individual relative activity in 2 subjects of CYP2D6*5/*10 were less than 30%.
Simulation of the exposures of unbound tolterodine, 5-HM and active moiety with changing intrinsic clearance of CYP2D6
Once CLint of EM (CYP2D6*1/*1) and PM (CYP2D6*4/*4) are determined, the AUC in IM can be simulated by changing CLint CYP2D6 from EM to PM. The simulated AUCs of unbound tolterodine, unbound 5-HM and active moiety with changing CLint CYP2D6 are shown in Figure 4 . The observed mean AUCs of each genotype in the present study were plotted at the reduction rate of CLint CYP2D6,tolterodine from CYP2D6*1/*1 (100% -relative activity in Table 3 ).
In the simulation, tolterodine AUC continued to increase from the exposure in EM (CYP2D6*1/*1) to the exposure in PM (CYP2D6*4/*4) with decreasing CLint CYP2D6
( Figure 4 ). The exposure increased steeply from about 80% reduction in CLint CYP2D6 .
For 5-HM, from the level in EM, AUC increased to the peak with decreasing enzyme activity around 80% reduction in CLint CYP2D6 , and fell to zero. As active moiety, the sum of unbound fraction of tolterodine and 5-HM, the exposure described a curve with the peak around 90% reduction in CLint CYP2D6 and the exposure at the peak was 1.9-fold higher than EM. It was simulated that the exposures in EM and PM were almost comparable whereas those in IMs (CYP2D6*1/*10, CYP2D6*1/*4 or CYP2D6*1/*5, CYP2D6*10/*10 and CYP2D6*5/*10) who had reduced enzyme activity were higher than the exposures in EM and PM. The simulated AUC in IMs were well matched with the observed IM values in the present study and the highest simulated active moiety exposure was around the observed value of CYP2D6*5/*10.
We used the reported mean values of fu tolterodine and fu 5-HM for this simulation (see Method section). When fu tolterodine and fu 5-HM are changed from minimum (fu tolterodine :
0.016 and fu 5-HM : 0.21) to maximum (0.063 and 0.52, respectively) in the present study, the maximum increase of the active moiety from EM (2.3-fold) was similar to the result of mean fu tolterodine and fu 5-HM (1.9-fold).
Discussion
This is the first report of clinical study to demonstrate the impact of CYP2D6*10 allele on tolterodine and 5-HM exposures. We also provided the first example of which IM shows higher exposure to pharmacological active moiety than EM and PM.
In the present study, we found spontaneous incidences of CYP2D6*10 in Asians ( Shen et al., 2007) , at least for tolterodine and 5-HM, it was expected that the relative enzyme activity of CYP2D6*10 compare to CYP2D6*1 were the same.
In the simulation with the estimated CLint CYP2D6 , in contrast with continuous increase of tolterodine exposure with decreasing enzyme activity, the 5-HM exposure described a curve with a peak (Figure 4) . It was considered that the effect of enzyme activity reduction on elimination of 5-HM (enhancement of the exposure) was dominant in the area from mild to moderate reduction, and the reducing effect on production of 5-HM (reduction of the exposure) became dominant when the reduction was excessive. From our simulation results, the peak of 5-HM exposure after administration of tolterodine was estimated at about 80% reduction in CLint CYP2D6 , it was between CYP2D6*10/*10 and CYP2D6*5/*10 in the present study. When the enzyme activity reduction was mild
to moderate, active moiety exposure increased with decreasing enzyme activity because both tolterodine and 5-HM increased with decreasing enzyme activity. When the enzyme activity reduction was excessive, the 5-HM exposure fell to zero, but active moiety exposure was still higher than that in CYP2D6*1/*1 due to compensation by steep increase of tolterodine. As a result, it was simulated that all IMs (CYP2D6*1/*10, CYP2D6*1/*4 or CYP2D6*1/*5, CYP2D6*10/*10 and CYP2D6*5/*10) had higher active moiety exposure than those in EM (CYP2D6*1/*1) and PM (CYP2D6*4/*4).
This simulation result was well matched with observed phenomenon in the present study and the highest simulated active moiety exposure was around the observed value of CYP2D6*5/*10.
With regard to the Cmax of 5-HM, no differences were observed among genotypes although AUCs in IMs were higher than EM. This is possibly explained as follows: The formulation was sustained release formulation and the releasing of tolterodine could be considered as infusion. The 5-HM Cmax is determined by this infusion rate and clearances for tolterodine and 5-HM which are influenced by genotype. On the other hand, the 5-HM AUC is determined by only the clearances. Under this circumstance, it is possible that Cmaxs were observed the same but AUCs were different among genotypes.
In the present study, as a result of a 3-fold increase of tolterodine exposure and 1.5-fold increase of 5-HM exposure, active moiety exposure which is the sum of unbound fraction of tolterodine and 5-HM was 1.8 fold in subjects with CYP2D6*10/*10 than CYP2D6*1/*1 and this was also higher than CYP2D6*4/*4 ( Figure 3 and Table 2 ). In the simulation, the highest simulated active moiety exposure was around the observed value of CYP2D6*5/*10 and it was 1.9-fold higher than EM (CYP2D6*1/*1). Although such difference in exposure could cause the difference of optimal doses between Western and Asian countries, the approved Asian dosage and administration is the same as the US/EU, a once a daily dose of 4 mg tolterodine PR capsule This article has not been copyedited and formatted. The final version may differ from this version. 
